Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 19/20 | 0.53 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10007447 | 0.90 | DGAT1 (0.60) | DGAT1SOAT1KCNH2 | |
| SCHEMBL10177264 | 0.86 | DGAT1 (0.57) | DGAT1 | |
| SCHEMBL15228884 | 0.84 | DGAT1 (0.52) | DGAT1SOAT1KCNH2 | |
| SCHEMBL10176555 | 0.83 | DGAT1 (0.52) | DGAT1SOAT1KCNH2 | |
| SCHEMBL9936443 | 0.82 | DGAT1 (0.53) | DGAT1SOAT1KCNH2 | |
| Acetic Acid SCHEMBL9936510 | 0.81 | DGAT1 (0.49) | DGAT1SOAT1KCNH2 | |
| SCHEMBL16660947 | 0.80 | MKNK1 (0.63) | DGAT1SOAT1KCNH2 | |
| SCHEMBL16661033 | 0.79 | DGAT1 (0.62) | DGAT1SOAT1KCNH2 | |
| SCHEMBL18541134 | 0.79 | DGAT1 (0.62) | DGAT1SOAT1KCNH2 | |
| SCHEMBL16661050 | 0.78 | DGAT1 (0.59) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477498-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172369-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2012-07-05 | — | — | US | disclosed |
| US-20120172369-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2012-07-05 | — | — | US | disclosed |
| US-20120172369-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2012-07-05 | — | — | US | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011031628-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031628-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172369-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT1 11/4885KCNH2 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.